Howdy, Stranger!

It looks like you're new here. If you want to get involved, click one of these buttons!

Loosen Up And Put Your Feet Up Whilst Grasping The Tricks Of Oxygenase

2,3,7 The direct renin inhibitor aliskiren offers an alternative to ACE inhibitors or ARBs for RAAS inhibition. Aliskiren acts at the rate-limiting step of the RAAS, and so reduces plasma renin NU7441 purchase activity (PRA; the rate of conversion of angiotensinogen to angiotensin [Ang] I by renin, expressed in ng/mL/h) as well as all downstream components of the RAAS (Ang I and II, plus aldosterone).17 Aliskiren may therefore provide greater RAAS inhibition than ACE inhibitors or ARBs, both of which increase PRA.17 All RAAS inhibitors increase plasma renin concentration (PRC; the amount of renin in a plasma sample, expressed in pg/mL) as they disrupt the negative feedback loop by which Ang II inhibits renin release from the kidney. Our study evaluated the efficacy, safety, and tolerability of single-pill combination therapy (also referred to as fixed-dose combination therapy) with aliskiren and hydrochlorothiazide (HCTZ) in patients with stage?2 systolic hypertension and DM. The primary objective of this randomized double-blind study was to determine whether once-daily treatment with aliskiren/HCTZ 300/25?mg was noninferior to amlodipine 10?mg in reducing mean sitting SBP (msSBP) after 8?weeks�� treatment in patients with stage?2 systolic hypertension (msSBP?��160?mm?Hg and <200 mm?Hg) and stable type?2 DM. <a href="">Oxygenase Men and women 18?years and older with stage 2 systolic hypertension (msSBP?��160?mm?Hg and <?200?mm?Hg) <a href=""> and type?2 DM (glycosylated hemoglobin [HbA1c] ��9%; treated with an antidiabetic regimen or on a stable diet and exercise program for at least 4?weeks before screening) were eligible for inclusion. The main exclusion criteria included severe hypertension (msSBP?��200?mm?Hg and/or mean sitting diastolic BP [msDBP]?��110?mm?Hg); secondary hypertension; history of hypertensive encephalopathy or heart failure (New York Heart Association class II�CIV); cerebrovascular disease, transient ischemic attack, or myocardial infarction within the year prior to screening; baseline serum potassium <3.5?mmol/L?or ��5.3?mmol/L; and known liver or kidney disease. Pregnant or lactating women were excluded from the study, while women of childbearing potential had to be using effective contraceptive methods for inclusion. All patients provided written informed consent before participating in any study procedures. The study was conducted in accordance with the International Conference on Harmonization Guidelines for Good Clinical Practice and the Declaration of Helsinki and received approval from the independent ethics committee or institutional review board at each study center. The trial is registered with (identifier: NCT00787605). This randomized, double-blind, active-controlled, parallel-group study was conducted at 153 centers in the United States.</div>
Sign In or Register to comment.